Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-481, 715 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CP-481,715 | DRUG | - |
Inclusion Criteria: * A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST. Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic,...
CP-481,715 is an investigational small molecule being studied for the treatment of allergic contact dermatitis, a type of skin inflammation caused by an allergic reaction to substances like nickel. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CP-481,715 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for allergic contact dermatitis.
CP-481,715 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of allergic contact dermatitis.
CP-481,715 has one completed Phase 1 clinical trial registered as NCT00141180, titled "CP-481,715 Nickel Allergy Study." The trial enrolled 48 participants with allergic contact dermatitis and was conducted in the United States and Denmark.
CP-481,715 is a unique investigational compound developed by Pfizer. No alternative names for this drug have been disclosed in clinical trial registrations. It is being studied specifically for allergic contact dermatitis and is not known to be marketed under any other name.